Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: Business Wire
Study shows blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90%Results pave the way for first potential FDA-approved blood test for colorectal cancer screening to meet requirements for Medicare coverage PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that results from the ECLIPSE study showing the effectiveness of its ShieldTM blood test for detecting colorectal cancer (CRC) in average-risk adults will be published in the March 14 issue of The New England Journal of Medicine.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240313547689/en/Shield (TM) from Guardant Health is a blood test for colorectal cancer screening for adults age 45-84 who are at average risk. (Photo: Business Wire)“Over 50 million eligible Americans do not get recommended screenings for colorectal cancer, partly because curre
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- Guardant Health, Inc. (NASDAQ: GH) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $28.00 price target on the stock.MarketBeat
- Amplifier Security emerges from stealth to bridge divide between the workforce and security with AI copilot and human-in-the-loop automation [Yahoo! Finance]Yahoo! Finance
- Putting The Human Touch Back Into Cybersecurity With Amplifier [Forbes]Forbes
- FDA Advisory Panel Review of Guardant Health's Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23 [Yahoo! Finance]Yahoo! Finance
- FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23Business Wire
GH
Earnings
- 2/22/24 - Beat
GH
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- GH's page on the SEC website